Feed IBRX
IB

ImmunityBio IBRX · NASDAQ

$8.31 -3.82% (-$0.33)

Market cap
$8.92B
Enterprise value
$9.66B
P/E
-
Forward P/E
-
PEG
-
P/S
53.8x
P/FCF
-
EV/EBITDA
-
ROIC
-45.0%
Bruto marža
94.6%
Neto marža
-598.6%
Dividend yield
-
Payout ratio
-
Neto dolg/EBITDA
-
Beta
0.13
Free float
10.9%

O podjetju

ImmunityBio, Inc. (IBRX) is a biotechnology company specializing in the development of immunotherapeutic treatment therapies for various types of cancer and infectious diseases. The company is engaged in developing innovative approaches that activate patients' immune systems and help them fight diseases. ImmunityBio develops drugs that can stimulate immune response, enhance treatment efficacy, and increase the chances of successful outcomes. With the growing research in the field of immunotherapy and the need for new treatment approaches, ImmunityBio, Inc. has the potential for sustained growth. ImmunityBio, Inc. (IBRX) shares might be an interesting choice for investors seeking involvement in the biotechnology and immunotherapeutic treatment therapies industry.

Sector

Healthcare

Industry

Biotechnology

CEO

Richard Gerald Adcock

Employees

688

Headquarters

San Diego

Vrednotenje

Je današnja cena primerna?

Rast in ocene

Ali podjetje raste in kaj sledi?

Donosnost in kakovost

Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?

Finančno zdravje

Ali zmore svoj dolg?

Kapital in dividende

Kaj podjetje počne z zasluženim denarjem?

Analitiki

Kaj menijo strokovnjaki in ali se to spreminja?

Lastniki in insajderji

Kdo ima delnice in kaj počne vodstvo?

Segmenti

Kateri del podjetja raste?

Primerjava s konkurenco

Kako se primerja s podobnimi podjetji?

Cena in tveganje

Kako se delnica obnaša?

Izkazi

Vse številke

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.